Actuate Therapeutics Reports $5.6 Million Net Loss in Q1 2026, Focuses on Clinical Development

Actuate Therapeutics, Inc. reported a net loss of $5.6 million for the first quarter of 2026, a decrease from the $6.3 million loss recorded in the same period of 2025. The company's total operating expenses for the quarter were approximately $5.7 million, down from $6.4 million year-over-year. This reduction in expenses was primarily driven by a significant decrease in research and development costs, which fell to $2.6 million from $3.2 million, attributed to lower patient fees and costs associated with fewer patients enrolled in clinical studies. General and administrative expenses remained relatively stable, totaling $3.1 million compared to $3.1 million in the prior year.

Actuate's financial position showed a decline in cash and cash equivalents, which decreased to $8.1 million as of March 31, 2026, down from $13.2 million at the end of 2025. The company’s total assets also fell to $8.9 million from $14.0 million, while total liabilities decreased to $5.1 million from $6.1 million. The accumulated deficit increased to $160.2 million, reflecting the ongoing investment in research and development without generating revenue from product sales. The company has not yet generated any revenue since its inception and continues to rely on external financing to support its operations.

In terms of strategic developments, Actuate Therapeutics has made progress in its clinical programs, particularly with its lead product candidate, elraglusib. The company has treated over 500 patients with elraglusib in various clinical studies and is advancing an oral formulation of the drug, which has received FDA clearance for a Phase 1/2 clinical study. The company aims to explore multiple cancer indications, including metastatic pancreatic ductal adenocarcinoma (mPDAC), with promising results reported in recent studies. Actuate has also entered into an At Market Issuance Sales Agreement, allowing it to raise up to $100 million through the sale of common stock, of which it raised approximately $519,624 in the first quarter of 2026.

Operationally, Actuate has focused on enhancing its research capabilities, with a notable increase in nonclinical and biomarker studies. The company reported a rise in personnel and consulting expenses due to increased headcount and medical consulting related to ongoing regulatory filings. As of March 31, 2026, the company had approximately 23.7 million shares of common stock outstanding, reflecting a slight increase from the previous quarter. Actuate's management anticipates that its cash reserves will not be sufficient to meet operational needs beyond July 2026 without additional capital, highlighting the importance of ongoing fundraising efforts.

Looking ahead, Actuate Therapeutics remains committed to advancing its clinical programs and exploring additional financing options to support its operations. The company acknowledges the inherent uncertainties in drug development and the potential for increased expenses as it seeks regulatory approval for elraglusib and potentially expands its product pipeline. The management's outlook emphasizes the need for continued capital raising efforts to sustain operations and fund future growth initiatives.